Form 4: Athira Pharma's Chief Scientific Officer, Kevin Church, Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Kevin Church, Chief Scientific Officer of Athira Pharma, reports the acquisition of stock options and restricted stock units.
Summary
- Kevin Church, the Chief Scientific Officer of Athira Pharma, filed a Form 4 detailing changes in beneficial ownership.
- On March 3, 2025, Church acquired stock options for 87,845 shares of common stock at an exercise price of $0.3762.
- These options vest monthly over 48 months from the grant date, contingent upon continued service.
- Church also acquired 58,563 restricted stock units (RSUs), each representing one share of Athira Pharma's common stock.
- These RSUs vest 100% on the one-year anniversary of the grant date, also contingent upon continued service.
- Following these transactions, Church directly owns 87,845 stock options and 58,563 RSUs.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reflects a standard executive compensation practice. The grants incentivize the executive but don't inherently indicate positive or negative news about the company's performance.
Positives
- The grant of stock options and RSUs to the Chief Scientific Officer aligns his interests with those of the shareholders.
- Vesting schedules tied to continued service incentivize long-term commitment.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in the pharmaceutical industry to incentivize key personnel.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation practices in the biotech industry, often used to attract and retain talent.
- Vesting schedules, such as the 48-month monthly vesting for options and one-year cliff vesting for RSUs, are typical in similar companies.
- Comparable companies like Biogen or Amgen also utilize equity-based compensation extensively.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of transaction (grant of stock options and RSUs) |
| 03/02/2035 | Expiration date of stock options |
| 03/04/2025 | Date of Form 4 filing |
Keywords
Form 4, Athira Pharma, Kevin Church, Stock Options, Restricted Stock Units, Beneficial Ownership, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.